Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Dr. Rachel Tate uptoTate
3 years 1 month ago
Early AMPLE study proteomic analysis showed 3 potential biomarkers (ANGPT1, TNFRSF10C, and GIF) for predicting CV risk/RA tx response to ABA vs ADA in Abs 0244. Possible new markers for personalized medicine? Can't wait to see more! #ACR22 @RheumNow https://t.co/QRpjJWzNYH https://t.co/6t6SDbouII
Dr. Rachel Tate uptoTate
3 years 1 month ago
Abs 0251 shows serum NFATc1 assoc'd w/ lipid panel abnormalities & inc CVD risk in early RA pts. I have so many questions regarding clinical use. This is compelling, especially if we can correlate changes in NFATc1 level with treatments. #ACR22 @RheumNow https://t.co/z0fU5TZAiU
TheDaoIndex KDAO2011
3 years 1 month ago
The Navajo Nation has 1 rheumatologist - equitably they need 19 since #RA is 3 times more prevalent! - Dr. J Mandal #ACR22 @rheumnow https://t.co/QcAVJzd4YY https://t.co/zMuZMtl6KC
Dr. Rachel Tate uptoTate
3 years 1 month ago
BIOBADASER 3.0 registry analysis shows risk of incident cancer in patients with rheumatic diseases and previous malignancy did not differ between TNFi or other b/tsDMARDs. Exciting, real-world data. Abs 0267 #ACR22 @RheumNow https://t.co/vZIN3U0QED https://t.co/EM1xXOv0Yd
Dr. Rachel Tate uptoTate
3 years 1 month ago
Alternate-day GC in IgG4-RD reduced GC-related AEs (adjusted for cumulative GC doses) w/o increase in dz flares particularly when combined w/ immunosuppressants. Possible new tx strategy for clinic? Need more data re: long-term dz Abs 0128 #ACR22 @RheumNow https://t.co/a1c1ZDeOCK https://t.co/3deUugpcVW
Bella Mehta bella_mehta
3 years 1 month ago
CAR-T cells in #sle - talk of the town this year!
reset the immune system?
deep depletion CD19+ B cell and tissue plasmablasts.
5 pts with SLE - drug free remission at 8 months.
Costs and risks still limiting use widely.
year in review #ACR22 @rheumnow https://t.co/ophgPjCDuF
Bella Mehta bella_mehta
3 years 1 month ago
Data from - CARRA registry sJIA-Lung Disease cohort -
Affects 1 in 20 pts - Interstitial lung disease (ILD) and pulmonary alveolar proteinosis (PAP).
13 pts - common features - tachypnea, clubbing, cough, finger and toe erythema
#MAS in 56% pts.
@RheumNow #ACR22 abst#0864 https://t.co/Q8fEzOkjJ7
Richard Conway RichardPAConway
3 years 1 month ago
Sode et al Mortality in GCA. Dominated by CV disease and higher than controls. Less cancer than controls @rheumnow #ACR22 Abstr#0467 https://t.co/TsfTWFRxJ2 https://t.co/lCZgVTpKUY
Richard Conway RichardPAConway
3 years 1 month ago
Kaeley et al. Evaluation of success of RA treatment. 69% LDA, 17% MDA, 14% HDA. Common barriers - medication access 27%, non-adherence 20%, co-morbidities 20%, non-inflammatory pain 13% @rheumnow #ACR22 Abstr#0077 https://t.co/c7euuzSx1m https://t.co/9ZN14ph5kI
Eric Dein ericdeinmd
3 years 1 month ago
@AlexisOgdie at #ACR22:
Ab0189 Ignite 🔥
PEST screening in patients with PsO w/o diagnosis of PsA - captures pts at highest risk. Decrease QoL, higher co-morbdities
High sensitivity test for screening
But is it capturing other co-morbidities (obesity, depression?)
@RheumNow
sheila RHEUMarampa
3 years 1 month ago
What factors influence visit preferences in pts w/ rheumatic dse? @rheumarhyme @doktora_ging
Interesting findings by Dr MDanila et al:
👉In-person visits due to org/clinic level influences
👉#telemedicine visits due to individual level influences
#ACR22 @RheumNow ABST0193 https://t.co/HcCUeahH8L
Olga Petryna DrPetryna
3 years 1 month ago
Pregnancy associated back pain and fatigue during 3rd trimester of pregnancy may affect accuracy of BASDAI score in women with AS. Morning stiffness has the highest classification value #ABS0374 #ACR22 @RheumNow https://t.co/DozZ6bxSU3
Richard Conway RichardPAConway
3 years 1 month ago
Rhee et al. MRI can, and frequently does, visualise enhancement in multiple cranial arteries @rheumnow #ACR22 Abstr#0473 https://t.co/iTtvl2DSoi https://t.co/tUV2zYIO8y
Richard Conway RichardPAConway
3 years 1 month ago
Brunetta et al. Is serum ANCA assoc malignancy? No @rheumnow #ACR22 Abstr#0450 https://t.co/dCJUZVvAqy https://t.co/K27Rk5tLSU
Richard Conway RichardPAConway
3 years 1 month ago
Levinson et al. Comparative risks of Alzheimers in inflammatory diseases. SLE (OR 1.31) and IBD (OR 1.17) higher risk than controls, RA, or PsO/PsA @rheumnow #ACR22 Abstr#0062 https://t.co/PbRa033e0L https://t.co/ENycKG4cyQ
Poster Hall